1 469

Cited 9 times in

Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer

Authors
 Jeong Youp Park  ;  Seung Woo Park  ;  Jae Bock Chung  ;  Jinsil Seong  ;  Kyung Sik Kim  ;  Woo Jung Lee  ;  Si Young Song 
Citation
 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.29(3) : 240-245, 2006 
Journal Title
 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 
ISSN
 0277-3732 
Issue Date
2006
MeSH
Administration, Oral ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Bile Duct Neoplasms/drug therapy* ; Bile Duct Neoplasms/radiotherapy* ; Bile Ducts, Extrahepatic* ; Combined Modality Therapy ; Female ; Floxuridine/administration & dosage ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Paclitaxel/administration & dosage ; Survival Analysis ; Treatment Outcome
Keywords
chemoradiotherapy ; doxifluridine ; paclitaxel ; extrahepatic bile duct cancer
Abstract
OBJECTIVES: Bile duct cancer is a rare malignancy with poor prognosis. We sought to determine the efficacy of concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. METHODS: Nineteen patients with unresectable extrahepatic bile duct cancer received doxifluridine (600 mg/m2) daily, intravenous paclitaxel (50 mg/m) weekly (before radiotherapy), and radiotherapy of 4500 cGy for approximately 5 weeks. RESULTS: Local response rate which reflected the reopening of occluded bile duct was 89.5% (17 out of 19). In 6 cases (31.6%), overall response, which measured the change of tumor size, was achieved with this treatment. The longest survival time was 52 months, and median survival time was 14 months. One- and 2-year survival rates were 84.2% and 31.6%, respectively. One case of gastrointestinal bleeding and 1 case of grade III leukopenia occurred during the treatment. One patient could not finish the treatment because of poor general condition. CONCLUSIONS: Concurrent chemoradiotherapy with doxifluridine and paclitaxel seemed to produce a good clinical response without severe toxicity and improve survival rates in patients with extrahepatic bile duct cancer.
Full Text
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000421-200606000-00005&LSLINK=80&D=ovft
DOI
10.1097/01.coc.0000217829.77404.22
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Kyung Sik(김경식) ORCID logo https://orcid.org/0000-0001-9498-284X
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Lee, Woo Jung(이우정) ORCID logo https://orcid.org/0000-0001-9273-261X
Chung, Jae Bock(정재복)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/110770
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links